Commentary
Volume 14:04, 2024

Transplantation Technologies & Research

ISSN: 2161-0991 Open Access

Lung Single-cell Transcriptomics Provides New Insights into Pulmonary Interstitial Toxicity

Goldfless Skalka*

Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia

Introduction

Lung diseases, particularly those involving interstitial toxicity, present significant challenges for medical research and clinical treatment. Pulmonary interstitial toxicity, which refers to damage to the lung's interstitial tissue, can arise from a variety of causes, including infections, environmental toxins, drugs, and autoimmune diseases. Traditionally, understanding the mechanisms underlying such toxicity has been limited by the inability to comprehensively analyze the complex cellular and molecular interactions occurring within the lung tissue. However, with the advent of single-cell transcriptomics, researchers are now able to gain unprecedented insights into these processes at a much higher resolution. One of the key advantages of single-cell transcriptomics is its ability to reveal the heterogeneity of lung cells involved in pulmonary interstitial toxicity. The lung is a complex organ composed of multiple cell types, including epithelial cells, endothelial cells, fibroblasts, macrophages, dendritic cells, and T cells. Each of these cells plays a distinct role in maintaining lung homeostasis, responding to injury, and promoting healing. In the context of interstitial toxicity, this diversity becomes particularly important [1].

Description

Single-cell RNA sequencing have uncovered how different immune and non-immune cells in the lung react to toxic insults. In response to injury, fibroblasts may become activated and contribute to fibrosis, while macrophages and dendritic cells might drive inflammation. Understanding the transcriptional changes in these cells at an individual level helps identify early molecular markers of toxicity and uncover previously unrecognized signaling pathways that drive the progression of lung diseases like pulmonary fibrosis or acute lung injury (ALI). Single-cell transcriptomics has provided valuable insights into the molecular mechanisms driving pulmonary interstitial toxicity by linking gene expression profiles to specific cellular behaviors. Researchers have been able to identify key molecular pathways involved in the response to injury and toxicity, including pathways related to inflammation, oxidative stress, fibrosis, and immune activation. For example, inflammatory cytokines such as TNF-α and IL-6, which are produced by various immune cells in response to lung injury, have been shown to activate signaling pathways that promote tissue damage and fibrosis. Single-cell transcriptomics has allowed researchers to pinpoint the exact cell types and transcriptional networks that regulate these inflammatory responses, shedding light on potential therapeutic targets for mitigating lung toxicity and preventing long-term damage. Additionally, recent studies have identified Epithelial-to-Mesenchymal Transition (EMT) as a critical process in the development of pulmonary fibrosis. EMT is a process in which epithelial cells lose their characteristics and acquire a fibroblast-like phenotype, contributing to the thickening and scarring of lung tissue. Single-cell transcriptomics has enabled the identification of the specific genes and pathways that govern this transition, offering new insights into how fibrosis develops and potential avenues for intervention [2].

A major benefit of single-cell transcriptomics is its potential application in the study of drug-induced pulmonary toxicity. Many drugs, including chemotherapeutic agents, antibiotics, and immunosuppressants, are known to cause lung injury as a side effect. By applying single-cell RNA sequencing to lung tissue from patients exposed to these drugs, researchers can identify the cellular responses and molecular mechanisms responsible for toxicity. For example, researchers have used single-cell transcriptomics to study methotrexate-induced lung injury, revealing how specific cell populations are activated in response to the drug and providing insights into the early detection and prevention of toxicities. Understanding these mechanisms can lead to the development of more targeted therapies or personalized treatment plans that minimize the risk of drug-induced pulmonary toxicity. Moreover, by studying the unique gene expression profiles of individual patients, single-cell transcriptomics offers the potential for personalized medicine in the treatment of pulmonary diseases. Patients with interstitial lung disease may respond differently to treatment based on their unique cellular profiles, and single-cell analysis could provide the information needed to tailor therapies to their specific molecular needs, improving outcomes and reducing side effects [3].

Despite its promise, single-cell transcriptomics also faces several challenges, particularly when applied to complex tissues like the lung. One of the major hurdles is the need for high-quality tissue samples that are representative of the organ's cellular diversity. Furthermore, the vast amount of data generated by single-cell RNA sequencing requires sophisticated computational tools for analysis and interpretation. However, as technology advances, these challenges are being addressed, and the potential for single-cell analysis to revolutionize our understanding of pulmonary interstitial toxicity is rapidly growing. This study utilized two primary data sources, both provided by the Scientific Registry of Transplant Recipients (SRTR). The first source was a customized database derived from program-specific reports. This database contained detailed information from each biannual SRTR report for transplant centers in the United States, including metrics such as the number of candidates and recipients eligible for each report. It also included performance data both pre- and post-transplant, such as observed and expected outcomes, as well as statistical measures like the Standardized Mortality Ratios (SMRs) for individual centers, which are used to evaluate performance [4].

The second source of data was from the standard SRTR analysis files, which provide comprehensive information on all donors, waitlisted candidates, and transplant recipients across the United States. These data are submitted by members of the Organ Procurement and Transplantation Network (OPTN), which coordinates transplant activity in the U.S. Oversight of OPTN activities is managed by the Health Resources and Services Administration (HRSA), a division of the U.S. Department of Health and Human Services. SRTR contractors are responsible for compiling and analyzing this data for use in transplant research and evaluation [5].

Conclusion

In the future, integrating single-cell transcriptomics with other technologies, such as spatial transcriptomics, could provide even more detailed insights into the spatial organization of cells in the lung and their interactions within the tissue microenvironment. This would allow researchers to map the precise location of toxic damage and better understand how cells interact in response to injury. Lung single-cell transcriptomics is a transformative tool

***Address for Correspondence:** Goldfless Skalka, Department of Natural Sciences, Novosibirsk State University, 630090 Novosibirsk, Russia, E-mail: skalka@edu.ru*

Received: 23 October, 2024, Manuscript No. jttr-24-157214; **Editor Assigned:** 25 October, 2024, PreQC No. P-157214; **Reviewed:** 08 November, 2024, QC No. Q-157214; **Revised:** 13 November, 2024, Manuscript No. R-157214; **Published:** 20 November, 2024, DOI: 10.37421/2161-0991.2024.14.282

in understanding pulmonary interstitial toxicity, offering a level of resolution previously unattainable with traditional methods. By examining gene expression at the single-cell level, this technique has revealed crucial insights into the complex interactions between different cell types involved in lung injury and fibrosis. It has enhanced our understanding of how specific immune and non-immune cells contribute to the development and progression of interstitial lung diseases, including pulmonary fibrosis and acute lung injury. These insights have the potential to lead to the identification of novel therapeutic targets and biomarkers, ultimately improving diagnostic accuracy and treatment strategies. As technology continues to evolve, integrating single-cell transcriptomics with other methods such as spatial transcriptomics could provide even deeper insights into the spatial organization and cellular interactions in lung tissue, paving the way for more personalized and effective treatments for pulmonary interstitial toxicity.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Springer, Ido, Nili Tickotsky and Yoram Louzoun. "Contribution of T cell receptor alpha and beta CDR3, MHC typing, V and J genes to peptide binding prediction." *Front Immunol* 12 (2021): 664514.
2. Kurilin, Vasily, Alina Alshevskaya and Sergey Sennikov. "Development of Cell Technologies Based on Dendritic Cells for Immunotherapy of Oncological Diseases." *Biomed* 12 (2024): 699.
3. Kuznetsova, Maria, Julia Lopatnikova, Julia Khantakova and Rinat Maksyutov, et al. "Generation of populations of antigen-specific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes." BMC *Immunol* 18 (2017): 1-13.
4. Obleukhova, Irina, Nataliya Kiryishina, Svetlana Falaleeva and Julia Lopatnikova, et al. "Use of antigen-primed dendritic cells for inducing antitumor immune responses in vitro in patients with non-small cell lung cancer." *Oncol Lett* 15 (2018): 1297-1306.
5. Carter, Jason A., Jonathan B. Preall, Kristina Grigaityte and Stephen J. Goldfless, et al. "Single T cell sequencing demonstrates the functional role of αβ TCR pairing in cell lineage and antigen specificity." *Front Immunol* 10 (2019): 1516.

How to cite this article: Skalka, Goldfless. "Lung Single-cell Transcriptomics Provides New Insights into Pulmonary Interstitial Toxicity." *J Transplant Technol Res* 14 (2024): 282.